Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy

References

• Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22:64–70.
   PubMedGoogle Scholar
• Matherly SC, Puri P. Mechanisms of simple hepatic steatosis: not so simple after all. Clin Liver Dis 2012;16:505–24.
   PubMedGoogle Scholar
• Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 2013;19:210–15.
   PubMedGoogle Scholar
• Wilkins T, Tadkod A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician 2013;88:35–42.
   PubMed Web of Science ®Google Scholar
• Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 2004;20:249–59.
   PubMedGoogle Scholar
• Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15:539–43.
   PubMed Web of Science ®Google Scholar
• Browning JD. New imaging techniques for non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:607–19.
   PubMedGoogle Scholar
• Roldan-Valadez E, Favila R, Martínez-López M, Uribe M, Méndez-Sánchez N. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol 2008;7:212–20.
   PubMed Web of Science ®Google Scholar
• Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433–45.
   PubMed Web of Science ®Google Scholar
• Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825–35.
   PubMed Web of Science ®Google Scholar
• Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012;36:13–20.
   PubMed Web of Science ®Google Scholar
• Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat 2012;19:244–53.
   PubMed Web of Science ®Google Scholar
• Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012;32:902–10.
   PubMed Web of Science ®Google Scholar
• Boursier J, Calès P. Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat? Liver Int 2012;32:875–7.
   PubMedGoogle Scholar
• de Lédinghen V, Vergniol J, Foucher J. Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911–18.
   PubMed Web of Science ®Google Scholar
• Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L. Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography. Kidney Blood Press Res 2013;37:305–10.
   PubMed Web of Science ®Google Scholar
• Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol 2013;28:1194–201.
   PubMed Web of Science ®Google Scholar
• Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res 2013; doi: 10.1111/hepr.12094.
   PubMedGoogle Scholar
• Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014;34:102–9.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol 2013;25:1330–4.
   PubMedGoogle Scholar
• Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int 2013; doi:10.1111/liv.12305.
   PubMedGoogle Scholar
• Yilmaz Y, Eren F, Colak Y, Senates E, Celikel CA, Imeryuz N. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol 2012;47:1488–93.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.
   PubMed Web of Science ®Google Scholar
• No authors listed]. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15–20.
   PubMed Web of Science ®Google Scholar
• Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086–7.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y. Biomarkers for early detection of non-alcoholic steatohepatitis: implications for drug development and clinical trials. Curr Drug Targets 2013;14:1357–66.
   PubMed Web of Science ®Google Scholar
• El-Zayadi AR. Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol 2008;14:4120–6.
   PubMed Web of Science ®Google Scholar
• Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013;267:422–31.
   PubMed Web of Science ®Google Scholar
• Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013;267:767–75.
   PubMed Web of Science ®Google Scholar